A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma).

Response of patients with renal involvement by progressive systemic sclerosis to antihypertensive therapy.

Adult stem cell treatment of scleroderma.

PURPOSE OF REVIEW Provides an update of hematopoietic stem cell transplantation for systemic sclerosis from phase I/II studies and prospective randomized phase III trials, and introduces the concept of mesenchymal stem cells as potential therapy for autoimmune disease. RECENT FINDINGS Around 170 transplanted systemic sclerosis patients are registered in Europe. Most received autologous, perip...

The Effectiveness of Cognitive-Behavioral Therapy in Pain Self-Efficacy, Fatigue, Life Expectancy and Depression in Patients with Multiple Sclerosis (MS): A Randomized Controlled Clinical Trial

Objective: The present study was conducted to investigate the effectiveness of cognitive-behavioral therapy in pain self-efficacy, fatigue, life expectancy and depression in patients with multiple sclerosis (MS). Methods: In a semi-experimental research with a control group pretest-posttest design, 68 patients with multiple sclerosis (MS) were selected through convenience sampling from neurolo...

Dystrophic Calcinosis in a Patient with Scleroderma: Imaging Findings and Literature Review

 Subcutaneous calcinosis consists of abnormal calcium deposition in soft tissues and is one of the complications of scleroderma, especially in limited systemic sclerosis. It is one of the criteria of CREST syndrome (calcinosis cutis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia). A 44-year-old woman with systemic scleroderma for 20 years was presented with pain ...

Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen

Systemic sclerosis (SSc) can be a devastating disease with lethal complications such as interstitial lung disease (ILD). Therapeutic strategies include cyclophosphamide but patients are frequently refractory even to this aggressive immunosuppressant. Lafyatis et al published a 6-month open observational study of 15 patients with diffuse scleroderma receiving one course of rituximab (2 1 g withi...